Correlation Between Santhera Pharmaceuticals and Newron Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Santhera Pharmaceuticals and Newron Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Santhera Pharmaceuticals and Newron Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Santhera Pharmaceuticals Holding and Newron Pharmaceuticals SpA, you can compare the effects of market volatilities on Santhera Pharmaceuticals and Newron Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Santhera Pharmaceuticals with a short position of Newron Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Santhera Pharmaceuticals and Newron Pharmaceuticals.

Diversification Opportunities for Santhera Pharmaceuticals and Newron Pharmaceuticals

0.63

Correlation Coefficient

Santhera Pharmaceuticals  Newron Pharmaceuticals

Poor diversification

The 3 months correlation between Santhera and Newron is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Santhera Pharmaceuticals Holdi and Newron Pharmaceuticals SpA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Newron Pharmaceuticals and Santhera Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Santhera Pharmaceuticals Holding are associated (or correlated) with Newron Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Newron Pharmaceuticals has no effect on the direction of Santhera Pharmaceuticals i.e., Santhera Pharmaceuticals and Newron Pharmaceuticals go up and down completely randomly.

Pair Corralation between Santhera Pharmaceuticals and Newron Pharmaceuticals

Assuming the 90 days trading horizon Santhera Pharmaceuticals Holding is expected to generate 1.2 times more return on investment than Newron Pharmaceuticals. However, Santhera Pharmaceuticals is 1.2 times more volatile than Newron Pharmaceuticals SpA. It trades about 0.05 of its potential returns per unit of risk. Newron Pharmaceuticals SpA is currently generating about -0.05 per unit of risk. If you would invest  1,382  in Santhera Pharmaceuticals Holding on December 30, 2024 and sell it today you would earn a total of  108.00  from holding Santhera Pharmaceuticals Holding or generate 7.81% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Santhera Pharmaceuticals Holdi  vs.  Newron Pharmaceuticals SpA

Santhera Pharmaceuticals

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Santhera Pharmaceuticals Holding are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Santhera Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Newron Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Newron Pharmaceuticals SpA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Pair Trading with Santhera Pharmaceuticals and Newron Pharmaceuticals

The main advantage of trading using opposite Santhera Pharmaceuticals and Newron Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Santhera Pharmaceuticals position performs unexpectedly, Newron Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Newron Pharmaceuticals will offset losses from the drop in Newron Pharmaceuticals' long position.

The idea behind Santhera Pharmaceuticals Holding and Newron Pharmaceuticals SpA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.